Physician profile
Robert B Gordon
NPI 1528041654
$3,308.42
in general payments reported to CMS, 2019-2025
23 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,136 · 2020: $981 · 2021: $793 · 2022: $398.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $568.16 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $512.33 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $379.62 | 2019-2022 | |
| Lundbeck LLC | $359.33 | 2019-2021 | |
| Vanda Pharmaceuticals INC. | $321.33 | 2019-2022 | |
| Ironshore Pharmaceuticals INC. | $164.43 | 2019-2020 | |
| Bausch Health US, LLC | $146.11 | 2019-2021 | |
| Allergan, INC. | $124.48 | 2019-2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $124.34 | 2020-2022 | |
| Adlon Therapeutics L.P. | $110.16 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $88.22 | 2019-2020 | |
| Alkermes, INC. | $69.24 | 2019 | |
| Abbvie INC. | $64.89 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $46.43 | 2019-2022 | |
| Jazz Pharmaceuticals INC. | $43.35 | 2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $43.17 | 2020-2021 | |
| Eisai INC. | $35.33 | 2020 | |
| Supernus Pharmaceuticals, INC. | $28.79 | 2021 | |
| Noven Therapeutics, LLC | $21.61 | 2020 | |
| Indivior INC. | $16.37 | 2020 | |
| Neurocrine Biosciences, INC. | $15.33 | 2021 | |
| Almatica Pharma LLC | $14.29 | 2022 | |
| Vertical Pharmaceuticals, LLC | $11.11 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Gordon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.